Galapagos - GLPG Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $34.50
Forecasted Upside: 19.96%
Number of Analysts: 5
Breakdown:
1 Sell Ratings
3 Hold Ratings
1 Buy Ratings
0 Strong Buy Ratings

^$28.76 As of 04/26/2024 01:00 AM ET

▲ +0.13 (0.45%)

1 month | 3 months | 12 months

Get New Galapagos Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for GLPG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GLPG

^$34.50

▲ +19.96% Upside Potential

This price target is based on 5 analysts offering 12 month price targets for Galapagos in the last 3 months. The average price target is $34.50, with a high forecast of $38.00 and a low forecast of $31.00. The average price target represents a 19.96% upside from the last price of $28.76.

Current Consensus is Hold

The current consensus among 5 contributing investment analysts is to hold stock in Galapagos. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
1 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

11/4/2022

0 strong buy ratings
1 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

2/2/2023

0 strong buy ratings
1 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

5/3/2023

0 strong buy ratings
1 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

8/1/2023

0 strong buy ratings
1 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

10/30/2023

0 strong buy ratings
1 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

1/28/2024

0 strong buy ratings
1 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

3/28/2024

0 strong buy ratings
1 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

4/27/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/22/2024	Morgan Stanley	Reiterated Rating	Equal Weight ➝ Equal Weight	$38.00 ➝ $38.00	Low
3/28/2024	Bank of America	Reiterated Rating	Neutral ➝ Underperform	$41.00 ➝ $31.00	Low
3/7/2024	Morgan Stanley	Initiated Coverage	Equal Weight	$38.00	Low
1/2/2024	Bank of America	Boost Target	Neutral ➝ Neutral	$41.00 ➝ $44.00	Low
8/24/2023	Citigroup	Downgrade	Buy ➝ Neutral		Low
8/7/2023	Morgan Stanley	Lower Target	Equal Weight ➝ Equal Weight	$42.00 ➝ $40.00	Low
7/31/2023	Morgan Stanley	Reiterated Rating	Equal Weight ➝ Equal Weight	$42.00	Low
7/24/2023	Morgan Stanley	Reiterated Rating	Equal Weight ➝ Equal Weight	$42.00	Low
5/31/2023	888	Reiterated Rating	Maintains		Low
5/31/2023	UBS Group	Initiated Coverage	Neutral		Low
5/9/2023	Morgan Stanley	Lower Target		$44.00 ➝ $42.00	Low
5/5/2023	Raymond James	Upgrade	Market Perform ➝ Outperform		Low
2/27/2023	Morgan Stanley	Lower Target	Equal Weight	$57.00 ➝ $44.00	Low
2/27/2023	Royal Bank of Canada	Lower Target	Sector Perform	$53.00 ➝ $43.00	Low
1/23/2023	Jefferies Financial Group	Upgrade	Underperform ➝ Hold	$49.00 ➝ $47.20	Low
12/5/2022	JPMorgan Chase & Co.	Lower Target	Neutral ➝ Neutral	€65.00 ➝ €50.00	Low
11/11/2022	Deutsche Bank Aktiengesellschaft	Lower Target		€50.00 ➝ €40.00	Low
11/7/2022	Royal Bank of Canada	Lower Target	Sector Perform	$55.00 ➝ $53.00	Low
11/7/2022	Morgan Stanley	Lower Target	Equal Weight	$63.00 ➝ $57.00	Low
11/7/2022	Raymond James	Downgrade	Outperform ➝ Market Perform		Low
10/14/2022	Barclays	Lower Target	Equal Weight ➝ Equal Weight	€60.00 ➝ €50.00	Low
10/13/2022	Morgan Stanley	Boost Target	Equal Weight	$61.00 ➝ $63.00	Low
9/9/2022	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$80.00 ➝ $61.00	Low
8/15/2022	Morgan Stanley	Boost Target	Overweight	$79.00 ➝ $80.00	Low
8/8/2022	Royal Bank of Canada	Lower Target		$62.00 ➝ $55.00	Low
7/25/2022	Jefferies Financial Group	Downgrade	Hold ➝ Underperform		Low
7/15/2022	Morgan Stanley	Lower Target	Overweight	$80.00 ➝ $79.00	Low
5/12/2022	UBS Group	Boost Target	Neutral ➝ Neutral	€52.00 ➝ €70.00	High
5/12/2022	JPMorgan Chase & Co.	Boost Target	Neutral ➝ Neutral	€60.00 ➝ €65.00	High
2/28/2022	Morgan Stanley	Boost Target	Overweight	$77.00 ➝ $80.00	Medium
1/28/2022	Bryan, Garnier & Co	Upgrade	Sell ➝ Buy		High
1/27/2022	Citigroup	Upgrade	Neutral ➝ Buy		High
1/6/2022	Morgan Stanley	Lower Target	Overweight	$118.00 ➝ $77.00	Low
11/8/2021	Royal Bank of Canada	Boost Target	Sector Perform	$64.00 ➝ $65.00	Low
8/27/2021	UBS Group	Reiterated Rating	Neutral		Low
8/19/2021	Barclays	Downgrade	Overweight ➝ Equal Weight		High
8/11/2021	JPMorgan Chase & Co.	Reiterated Rating	Neutral		Low
8/9/2021	Royal Bank of Canada	Lower Target	Sector Perform	$87.00 ➝ $64.00	Low
8/6/2021	Deutsche Bank Aktiengesellschaft	Downgrade	Buy ➝ Hold	$50.00	Low
7/15/2021	Raymond James	Set Target	Buy	$65.80	High
6/7/2021	Barclays	Reiterated Rating	Overweight		Low
5/11/2021	JPMorgan Chase & Co.	Reiterated Rating	Neutral		Low
5/10/2021	Morgan Stanley	Boost Target	Overweight	$117.00 ➝ $118.00	High
4/20/2021	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy		Low
4/14/2021	Barclays	Upgrade	Equal Weight ➝ Overweight		Low
4/12/2021	UBS Group	Reiterated Rating	Neutral		Medium
3/11/2021	Morgan Stanley	Lower Target	Overweight	$129.00 ➝ $117.00	Low
3/2/2021	Barclays	Reiterated Rating	Equal Weight		Low
2/25/2021	Raymond James	Upgrade	Market Perform ➝ Outperform	$100.00	Low
2/23/2021	Bank of America	Upgrade	Underperform ➝ Neutral	$93.00 ➝ $94.00	Low
2/19/2021	Raymond James	Upgrade	Market Perform ➝ Outperform		Low
2/11/2021	UBS Group	Reiterated Rating	Neutral		Low
2/11/2021	Citigroup	Downgrade	Buy ➝ Neutral		Low
2/10/2021	Maxim Group	Downgrade	Buy ➝ Hold		Low
1/19/2021	Barclays	Boost Target	Equal Weight	$85.50 ➝ $125.00	Low
1/19/2021	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight		Medium
12/17/2020	Maxim Group	Lower Target		$140.00 ➝ $170.00	High
12/17/2020	Smith Barney Citigroup	Reiterated Rating	Buy		High
12/17/2020	Bryan, Garnier & Co	Downgrade	Buy ➝ Sell		High
11/23/2020	UBS Group	Reiterated Rating	Neutral		Low
11/19/2020	Maxim Group	Initiated Coverage	Buy	$170.00	Low
11/12/2020	JPMorgan Chase & Co.	Lower Target	Neutral	$152.00 ➝ $142.00	Medium
10/21/2020	The Goldman Sachs Group	Downgrade	Neutral ➝ Sell		Low
10/16/2020	UBS Group	Reiterated Rating	Neutral		Low
10/16/2020	Royal Bank of Canada	Lower Target	Sector Perform	$135.00 ➝ $131.00	High
10/13/2020	Barclays	Reiterated Rating	Equal Weight		Low
10/13/2020	Morgan Stanley	Boost Target	Equal Weight	$158.00 ➝ $159.00	Low
10/8/2020	UBS Group	Reiterated Rating	Neutral		Low
9/25/2020	Stifel Nicolaus	Reiterated Rating	Hold		Low
9/24/2020	JPMorgan Chase & Co.	Reiterated Rating	Neutral		Medium
9/11/2020	Stifel Nicolaus	Reiterated Rating	Hold		Low
8/25/2020	Jefferies Financial Group	Downgrade	Buy ➝ Hold		Low
8/24/2020	HC Wainwright	Downgrade	Buy ➝ Neutral	$270.00 ➝ $123.00	Low
8/21/2020	Morgan Stanley	Lower Target	Equal Weight	$221.00 ➝ $158.00	Low
8/21/2020	Bank of America	Lower Target	Underperform	$148.00 ➝ $134.00	Low
8/19/2020	Citigroup	Upgrade	Neutral ➝ Buy		High
8/19/2020	Cantor Fitzgerald	Lower Target	Neutral	$192.00 ➝ $134.00	High
8/19/2020	Barclays	Downgrade	Overweight ➝ Equal Weight		High
8/18/2020	Stifel Nicolaus	Reiterated Rating	Hold	$155.00	High
8/11/2020	Barclays	Reiterated Rating	Overweight		Medium
8/10/2020	Morgan Stanley	Lower Target	Equal Weight	$224.00 ➝ $221.00	Low
8/7/2020	Stifel Nicolaus	Reiterated Rating	Hold	$187.00	High
7/24/2020	HC Wainwright	Reiterated Rating	Buy	$270.00	Low
7/15/2020	Morgan Stanley	Lower Target	Equal Weight	$226.00 ➝ $224.00	Low
7/10/2020	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$298.00 ➝ $193.00	High
5/21/2020	Nomura	Reiterated Rating	Buy	$290.00	Medium
5/21/2020	HC Wainwright	Lower Target	Buy	$302.00 ➝ $270.00	High
5/18/2020	UBS Group	Reiterated Rating	Neutral		Medium
5/15/2020	Barclays	Reiterated Rating	Overweight		Low
4/15/2020	Morgan Stanley	Boost Target	Equal Weight	$220.00 ➝ $226.00	Low
4/13/2020	Royal Bank of Canada	Reiterated Rating	Hold	$155.00	Low
3/30/2020	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$232.00	Low
3/18/2020	Royal Bank of Canada	Upgrade	Underperform ➝ Sector Perform	$175.00 ➝ $157.00	Low
3/2/2020	JPMorgan Chase & Co.	Lower Target	Neutral	$205.00 ➝ $200.00	High
2/26/2020	Morgan Stanley	Boost Target	Equal Weight	$215.00 ➝ $220.00	Low
2/26/2020	Nomura Securities	Reiterated Rating	Buy	$209.00 ➝ $290.00	Low
2/25/2020	Cantor Fitzgerald	Downgrade	Overweight ➝ Neutral	$187.00 ➝ $192.00	High
2/24/2020	HC Wainwright	Reiterated Rating	Buy	$205.00 ➝ $302.00	High
2/24/2020	Citigroup	Downgrade	Neutral ➝ Underperform	$213.00	High
2/24/2020	Stifel Nicolaus	Reiterated Rating	Buy	$188.00 ➝ $298.00	High
2/24/2020	Bank of America	Downgrade	Neutral ➝ Underperform	$213.00	High
2/20/2020	Royal Bank of Canada	Downgrade	Sector Perform ➝ Underperform	$175.00	High
1/5/2020	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$205.00	N/A
12/20/2019	UBS Group	Downgrade	Buy ➝ Neutral		Low
12/18/2019	Citigroup	Downgrade	Buy ➝ Neutral		Low
12/17/2019	Morgan Stanley	Downgrade	Overweight ➝ Equal	$193.00 ➝ $215.00	Low
12/13/2019	Credit Suisse Group	Downgrade	Outperform ➝ Neutral	$174.00 ➝ $169.00	Medium
12/2/2019	Bank of America	Initiated Coverage	Neutral	$199.00	Low
11/15/2019	Royal Bank of Canada	Boost Target	Sector Perform	$152.00 ➝ $158.00	Low
10/29/2019	Morgan Stanley	Lower Target	Overweight	$193.00	Low
9/9/2019	Morgan Stanley	Initiated Coverage	Overweight	$200.00	Medium
7/31/2019	UBS Group	Upgrade	Neutral ➝ Buy		Low
7/29/2019	Nomura Securities	Boost Target	Buy	$140.00 ➝ $209.00	Medium
7/29/2019	Royal Bank of Canada	Boost Target		$171.00	Low
7/29/2019	Jefferies Financial Group	Downgrade	Buy ➝ Hold		Low
7/26/2019	Cowen	Reiterated Rating	Buy		Low
7/15/2019	Raymond James	Downgrade	Strong-Buy ➝ Market Perform		Low
7/15/2019	Stifel Nicolaus	Boost Target	Buy	$121.00 ➝ $188.00	High
7/15/2019	HC Wainwright	Boost Target	Buy ➝ Buy	$150.00 ➝ $205.00	High
7/10/2019	Credit Suisse Group	Reiterated Rating	Outperform		Low
7/2/2019	HC Wainwright	Set Target	Buy	$150.00	Low
6/12/2019	HC Wainwright	Reiterated Rating	Buy	$150.00	Low
5/23/2019	HC Wainwright	Set Target	Buy	$150.00	Low
5/2/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$130.00	Low
4/29/2019	Morgan Stanley	Boost Target	Overweight ➝ Overweight	$138.00 ➝ $139.00	Low

(Data available from 4/28/2019 forward)

News Sentiment Rating

-0.03 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

3 very positive mentions
2 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

10/1/2023

1 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

10/31/2023

3 very positive mentions
8 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

11/30/2023

2 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

12/30/2023

5 very positive mentions
6 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/29/2024

3 very positive mentions
12 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

2/28/2024

2 very positive mentions
13 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

3/29/2024

2 very positive mentions
5 positive mentions
5 negative mentions
0 very negative mentions

Mentions as of

4/28/2024

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Today's Range

Now: $28.76

$28.34

$28.87

50 Day Range

MA: $33.08

$28.63

$39.66

52 Week Range

Now: $28.76

$28.33

$45.21

Volume

75,390 shs

Average Volume

138,597 shs

Market Capitalization

$1.90 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.24

Frequently Asked Questions

What sell-side analysts currently cover shares of Galapagos?: The following sell-side analysts have issued stock ratings on Galapagos in the last twelve months: 888 Holdings plc, Bank of America Co., Citigroup Inc., Morgan Stanley, Raymond James, StockNews.com, and UBS Group AG.
View the latest analyst ratings for GLPG.
What is the current price target for Galapagos?: 2 Wall Street analysts have set twelve-month price targets for Galapagos in the last year. Their average twelve-month price target is $34.50, suggesting a possible upside of 20.0%. Morgan Stanley has the highest price target set, predicting GLPG will reach $38.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $31.00 for Galapagos in the next year.
View the latest price targets for GLPG.
What is the current consensus analyst rating for Galapagos?: Galapagos currently has 1 sell rating, 3 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GLPG, but not buy more shares or sell existing shares.
View the latest ratings for GLPG.
What other companies compete with Galapagos?: Other companies that are similar to Galapagos include Maravai LifeSciences, PTC Therapeutics, NewAmsterdam Pharma, Geron and Keros Therapeutics. Learn More about companies similar to Galapagos.
How do I contact Galapagos' investor relations team?: Galapagos' physical mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company's listed phone number is (321) 534-2900 and its investor relations email address is [email protected]. The official website for Galapagos is www.glpg.com. Learn More about contacing Galapagos investor relations.

Galapagos - GLPG Stock Price Target and Predictions

Analyst Price Target for GLPG

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

-0.03 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Galapagos?

What is the current price target for Galapagos?

What is the current consensus analyst rating for Galapagos?

What other companies compete with Galapagos?

How do I contact Galapagos' investor relations team?